EcoDrugPlus

Hyperpolarization Activated Cyclic Nucleotide Gated Potassium Channel 4

Ensembl ID : ENSCHAG00000005183
Gene Symbol: HCN4
1 Cross references
219 Possible Orthologues:

Hyperpolarization Activated Cyclic Nucleotide Gated Potassium Channel 4

Ensembl ID : ENSCHAG00000010667
Gene Symbol: HCN4
1 Cross references
211 Possible Orthologues:

Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 Homolog

Ensembl ID : ENSCHAG00000020486
Gene Symbol: LOC105902025
3 Cross references
150 Possible Orthologues:

Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 Homolog

Ensembl ID : ENSCHAG00000006004
Gene Symbol: LOC105891947
3 Cross references
229 Possible Orthologues:

Inhibitor Of Nuclear Factor Kappa B Kinase Subunit Beta

Ensembl ID : ENSCHAG00000007905
Gene Symbol: IKBKB
3 Cross references
198 Possible Orthologues:

Inositol Polyphosphate-5-Phosphatase D

Ensembl ID : ENSCHAG00000016805
Gene Symbol: INPP5D
1 Cross references
216 Possible Orthologues:

Insulin Receptor A

Ensembl ID : ENSCHAG00000021370
Gene Symbol: INSRA
1 Cross references
231 Possible Orthologues:

Insulin Receptor B

Ensembl ID : ENSCHAG00000005950
Gene Symbol: INSRB
1 Cross references
201 Possible Orthologues:

Insulin-Like Growth Factor 1a Receptor

Ensembl ID : ENSCHAG00000020214
Gene Symbol: IGF1RA
1 Cross references
206 Possible Orthologues:

Insulin-Like Growth Factor 1b Receptor

Ensembl ID : ENSCHAG00000010686
Gene Symbol: IGF1RB
1 Cross references
204 Possible Orthologues:

Integrin Alpha-5-Like

Ensembl ID : ENSCHAG00000023337
Gene Symbol: LOC105906789
3 Cross references
206 Possible Orthologues:

Integrin Beta 3a

Ensembl ID : ENSCHAG00000008940
Gene Symbol: ITGB3A
1 Cross references
204 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).